NCT00559169撤回不适用
Study of Verapamil in Refractory Catamenial Epilepsy
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 入组人数
- 12
- 试验地点
- 2
- 主要终点
- the percent reduction in seizure frequency
研究概览
简要总结
One in 3 epilepsy patients have refractory seizures. This drug resistance is likely related to the over expression of multidrug resistance proteins (MDR). Progesterone is a known inhibitor of MDRs and the low level of this hormone during the menstrual cycle may exacerbate seizures, perhaps explaining catamenial epilepsy; i.e. seizures occurring during the menstrual cycle. Verapamil suppresses seizures in animal models of epilepsy perhaps by inhibiting MDRs and thus may help patients with refractory seizures. If the study shows improved seizure control, the results will help establish the role of MDRs in refractory epilepsy.
研究设计
- 研究类型
- Interventional
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 60 Years(Adult)
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •at least 2 seizures per month
- •more than 50% of the seizures occur 7 days before or 7 days after the onset of menses
- •patient of the Toronto Western Hospital Epilepsy Clinic
排除标准
- •cardiovascular history
结局指标
主要结局
the percent reduction in seizure frequency
时间窗: 3 months
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
Unknown
不适用
Study of Verapamil in Refractory EpilepsySeizuresEpilepsyNCT01126307University Health Network, Toronto16
终止
2 期
P-glycoprotein Inhibition as Adjunct Treatment for Medically Refractory Epilepsy.EpilepsyNCT00524134Columbia University6
已完成
3 期
Pharmacotherapy of Treatment-Resistant ManiaManiaNCT00518947University of Pittsburgh45
已完成
1 期
A Single-blind, Placebo-controlled, Outpatient Trial to Assess the Effects of Single Oral Tablet Dose of OPC-214870EpilepsyNCT04241965Otsuka Pharmaceutical Development & Commercialization, Inc.16
已完成
不适用
Development and clinical application of [11C]Verapamil-PET, a surrogate marker on p-glycoprotein expressioKCT0000994Seoul National University Hospital30
